In last trading session, Novavax, Inc (NASDAQ:NVAX) saw 6.38 million shares changing hands with its beta currently measuring 3.09. Company’s recent per share price level of $7.07 trading at -$0.4 or -5.35% at ring of the bell on the day assigns it a market valuation of $1.14B. That closing price of NVAX’s stock is at a discount of -237.48% from its 52-week high price of $23.86 and is indicating a premium of 44.84% from its 52-week low price of $3.90. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 7.75 million shares which gives us an average trading volume of 4.94 million if we extend that period to 3-months.

For Novavax, Inc (NVAX), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 2.14. Splitting up the data highlights that, out of 16 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 6 suggested the stock as a Hold whereas 10 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of 0.19 in the current quarter.

Novavax, Inc (NASDAQ:NVAX) trade information

Upright in the red during last session for losing -5.35%, in the last five days NVAX remained trading in the green while hitting it’s week-highest on Wednesday, 04/23/25 when the stock touched $7.07 price level, adding 9.48% to its value on the day. Novavax, Inc’s shares saw a change of -12.06% in year-to-date performance and have moved 14.03% in past 5-day. Novavax, Inc (NASDAQ:NVAX) showed a performance of -6.48% in past 30-days. Number of shares sold short was 36.88 million shares which calculate 9.51 days to cover the short interests.

Wall Street analysts have assigned a consensus price target of 22 to the stock, which implies a rise of 67.86% to its current value. Analysts have been projecting 22 as a low price target for the stock while placing it at a high target of 22. It follows that stock’s current price would drop -211.17% in reaching the projected high whereas dropping to the targeted low would mean a loss of -211.17% for stock’s current value.

Novavax, Inc (NVAX) estimates and forecasts

This year revenue growth is estimated to fall -16.07% from the last financial year’s standing.

4 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 204.07M for the same. And 4 analysts are in estimates of company making revenue of 155.18M in the next quarter. Company posted 93.86M and 415.48M of sales in current and next quarters respectively a year earlier.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 25.88% during past 5 years.

Novavax, Inc (NASDAQ:NVAX)’s Major holders

Insiders are in possession of 8.77% of company’s total shares while institution are holding 60.10 percent of that, with stock having share float percentage of 65.88%. Investors also watch the number of corporate investors in a company very closely, which is 60.10% institutions for Novavax, Inc that are currently holding shares of the company. VANGUARD GROUP INC is the top institutional holder at NVAX for having 14.08 million shares of worth $178.19 million. And as of 2024-06-30, it was holding 9.4861 of the company’s outstanding shares.

The second largest institutional holder is BLACKROCK INC., which was holding about 11.85 million shares on 2024-06-30. The number of shares represents firm’s hold over 7.984 of outstanding shares, having a total worth of $149.98 million.

On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and iShares Trust-iShares Russell 2000 ETF are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024 , the former fund manager was holding 4.79 shares of worth $33.84 million or 2.98% of the total outstanding shares. The later fund manager was in possession of 4.09 shares on Mar 31, 2025 , making its stake of worth around $28.94 million in the company or a holder of 2.55% of company’s stock.